Document Detail

Current development of podophyllotoxins.
MedLine Citation:
PMID:  7044596     Owner:  NLM     Status:  MEDLINE    
The unique biological properties and therapeutic efficacy of the podophyllotoxin derivatives, Vumon (VM26, teniposide) and Vepesid (VP16-213, etoposide), are stimulating the interest of both laboratory and clinical researchers. Investigations on new pharmaceutical formulations, pharmacokinetics and metabolism are providing more appropriate information in drug administration; experimental chemotherapy indicates that, among others, cytosine arabinoside and cisplatin are highly synergistic with podophyllotoxins; single agent and combination treatment clinical trials are defining the respective role of Vumon and Vepesid in cancer chemotherapy.
R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Related Documents :
17447426 - The use of rasagiline in parkinson's disease.
23541556 - Microbead design for sustained drug release using four natural gums.
19554866 - New zealand law's protection of drug trial participants.
16279756 - A call to restructure the drug development process: government over-regulation and non-...
22195116 - Adepedia: a scalable and standardized knowledge base of adverse drug events using seman...
3743576 - Social, toxicological and meteorological data on suicide attempts.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  7     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  1982  
Date Detail:
Created Date:  1982-08-26     Completed Date:  1982-08-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  93-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chemistry, Pharmaceutical
Drug Compounding
Drug Stability
Drug Synergism
Drug Therapy, Combination
Etoposide / metabolism,  pharmacology*
Podophyllotoxin / analogs & derivatives*
Teniposide / metabolism*,  pharmacology*
Reg. No./Substance:
29767-20-2/Teniposide; 33419-42-0/Etoposide; 518-28-5/Podophyllotoxin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The podophyllotoxin derivatives VP16-213 and VM26.
Next Document:  Resistance of Salmonella typhimurium TA 1535 to O6-guanine methylation and mutagenesis induced by lo...